Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. News
KalVista Pharmaceuticals, Inc. Quantitative Score
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
KalVista Pharmaceuticals, Inc. Financials
Table Compare
Compare KALV metrics with: | |||
|---|---|---|---|
Earnings & Growth | KALV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | KALV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | KALV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | KALV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
KalVista Pharmaceuticals, Inc. Income
KalVista Pharmaceuticals, Inc. Balance Sheet
KalVista Pharmaceuticals, Inc. Cash Flow
KalVista Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
KalVista Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Mr. Benjamin L. Palleiko | Chief Executive Officer & Director |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Mr. Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Benjamin L. Palleiko | Chief Executive Officer & Director | Male | 1966 | 983.07K |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer | 1973 | 736.82K | |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer | 1964 | 708.53K | |
| Mr. Brian Krex J.D. | General Counsel | Male | 1968 | -- |
| Jarrod Aldom | Vice President of Corporate Communications | -- |
KalVista Pharmaceuticals, Inc. Insider Trades
| Date | 22 Aug |
| Name | Sweeny Nicole |
| Role | Chief Commercial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 25 Aug |
| Name | Sweeny Nicole |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1480 |
| Date | 22 Aug |
| Name | Sweeny Nicole |
| Role | Chief Commercial Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 5000 |
| Date | 22 Aug |
| Name | Yea Christopher |
| Role | CHIEF DEVELOPMENT OFFICER |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 3125 |
| Date | 25 Aug |
| Name | Yea Christopher |
| Role | CHIEF DEVELOPMENT OFFICER |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1954 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 22 Aug | Sweeny Nicole | Chief Commercial Officer | Acquired | M-Exempt | 5000 |
| 25 Aug | Sweeny Nicole | Chief Commercial Officer | Disposed | S-Sale | 1480 |
| 22 Aug | Sweeny Nicole | Chief Commercial Officer | Disposed | M-Exempt | 5000 |
| 22 Aug | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Acquired | M-Exempt | 3125 |
| 25 Aug | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Disposed | S-Sale | 1954 |